224 reports of this reaction
2.0% of all FARICIMAB reports
#10 most reported adverse reaction
BLINDNESS is the #10 most commonly reported adverse reaction for FARICIMAB, manufactured by Genentech, Inc.. There are 224 FDA adverse event reports linking FARICIMAB to BLINDNESS. This represents approximately 2.0% of all 11,141 adverse event reports for this drug.
Patients taking FARICIMAB who experience blindness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BLINDNESS is a less commonly reported adverse event for FARICIMAB, but still significant enough to appear in the safety profile.
In addition to blindness, the following adverse reactions have been reported for FARICIMAB:
The following drugs have also been linked to blindness in FDA adverse event reports:
BLINDNESS has been reported as an adverse event in 224 FDA reports for FARICIMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
BLINDNESS accounts for approximately 2.0% of all adverse event reports for FARICIMAB, making it a notable side effect.
If you experience blindness while taking FARICIMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.